Kang JM, Tanna AP. Glaucoma. Med Clin North Am. 2021;105:493–510.

Article  PubMed  Google Scholar 

Suzuki Y, Yamamoto T, Araie M, Iwase A, Tomidokoro A, Abe H, et al. Tajimi Study review. Nippon Ganka Gakkai Zasshi. 2008;112:1039–58. (in Japanese).

PubMed  Google Scholar 

Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol. 2008;53(Suppl1):S3–10.

Article  PubMed  Google Scholar 

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13; discussion 829–30.

Heijl A, Leske MC, Bengtsson B, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Measuring visual field progression in the early manifest Glaucoma trial. Acta Ophthalmol Scand. 2003;81:286–93.

Article  PubMed  Google Scholar 

Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. Glaucoma Guideline Preparation Committee JGS. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189–254.

Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15:1737–47.

Article  PubMed  CAS  Google Scholar 

Hollo G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nakano T, Mizoue S, Fuse N, Iwase A, Matsumoto S, Yoshikawa K. Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: a prospective multicenter open-label study. Adv Ther. 2015;32:823–37.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sakamoto M, Kitamura K, Kashiwagi K. Changes in glaucoma medication during the past eight years and future directions in Japan based on an insurance medical claim database. J Ophthalmol. 2017;2017:7642049.

Article  PubMed  PubMed Central  Google Scholar 

Hasebe Y, Kashiwagi K, Tsumura T, Suzuki Y, Yoshikawa K, Suzumura H, et al. Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy. Patient Prefer Adherence. 2018;12:1567–77.

Article  PubMed  PubMed Central  Google Scholar 

Tsumura T, Kashiwagi K, Suzuki Y, Yoshikawa K, Suzumura H, Maeda T, et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39:375–83.

Article  PubMed  Google Scholar 

Hommer A. Role of fixed combinations in the management of open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2011;11:91–9.

Article  PubMed  Google Scholar 

Higginbotham EJ, Hansen J, Davis EJ, Walt JG, Guckian A. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin. 2009;25:2543–7.

Article  PubMed  CAS  Google Scholar 

Inoue K, Shiokawa M, Sugahara M, Wakakura M, Soeda S, Tomita G. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56:559–63.

Article  PubMed  CAS  Google Scholar 

Onoe H, Hirooka K, Nagayama M, Hirota A, Mochizuki H, Sagara T, et al. The efficacy, safety and satisfaction associated with switching from brinzolamide 1% and brimonidine 0.1% to a fixed combination of brinzolamide 1% and brimonidine 0.1% in glaucoma patients. J Clin Med. 2021;10:5228.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Onoe H, Hirooka K, Nagayama M, Mochizuki H, Hirota A, Suzuki K, et al. The efficacy, safety, and satisfaction associated with switching from brinzolamide or brimonidine to brinzolamide/brimonidine in open-angle glaucoma patients. J Pers Med. 2022;12:2057.

Article  PubMed  PubMed Central  Google Scholar 

Sakata R, Mizoue S, Yoshikawa K, Adachi M, Ohkubo S, Hamada N, et al. Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients. Jpn J Ophthalmol. 2023;67:668–77.

Article  PubMed  CAS  Google Scholar 

Inoue K, Kunimatsu-Sanuki S, Ishida K, Tomita G. Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications. Jpn J Ophthalmol. 2022;66:440–6.

Article  PubMed  CAS  Google Scholar 

Aoki R, Terao E, Dote S, Shiraishi M, Oogi S, Ueda K, et al. Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients. BMJ Open Ophthalmol. 2022;7:e001200.

Article  PubMed  PubMed Central  Google Scholar 

Cho HK, Park MH, Moon JI. Effects of antiglaucoma drugs on the ocular surface in rabbits: a fixed-combination drug versus two concomitant drugs. Jpn J Ophthalmol. 2011;55:670–5.

Article  PubMed  Google Scholar 

Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.

PubMed  CAS  Google Scholar 

Chen Y, Le Q, Hong J, Gong L, Xu J. In vivo confocal microscopy of toxic keratopathy. Eye (Lond). 2017;31:140–7.

Article  PubMed  CAS  Google Scholar 

Schwab IR, Abbott RL. Toxic ulcerative keratopathy. An unrecognized problem. Ophthalmology. 1989;96:1187–93.

Article  PubMed  CAS  Google Scholar